AAV gene therapy for Tay-Sachs disease
Open accessPublished version of a preprint
The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
Tay-Sachs disease (TSD) is an inherited neurological disorder caused by deficiency of hexosaminidase A (HexA). Here, we describe an adeno-associated virus (AAV) gene therapy expanded-access trial in two patients with infantile TSD (IND 18225) with safety as the primary endpoint and no secondary endpoints. Patient TSD-001 was treated at 30 months with an equimolar mix of AAVrh8-HEXA and AAVrh8-HEXB administered intrathecally (i.t.), with 75% of the total dose (1 × 10 14 vector genomes (vg)) in the cisterna magna and 25% at the thoracolumbar junction. Patient TSD-002 was treated at 7 months by combined bilateral thalamic (1.5 × 10 12 vg per thalamus) and i.t. infusion (3.9 × 10 13 vg). Both patients were immunosuppressed. Injection procedures were well tolerated, with no vector-related adverse events (AEs) to date. Cerebrospinal fluid (CSF) HexA activity increased from baseline and remained stable in both patients. TSD-002 showed disease stabilization by 3 months after injection with ongoing myelination, a temporary deviation from the natural history of infantile TSD, but disease progression was evident at 6 months after treatment. TSD-001 remains seizure-free at 5 years of age on the same anticonvulsant therapy as before therapy. TSD-002 developed anticonvulsant-responsive seizures at 2 years of age. This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Injection into other sites such as the central nervous system (CNS) may partially restrict the exposure to serum antibodies prior to target cell entry [16, 17].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [16]
In the citing paper
“Furthermore, in the clinical setting, ocular and intrathecal AAV gene delivery have shown limited transgene-related immune responses, possibly due to their compartmentation and reduced antigen presentation [16, 132, 133].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [16]
In the citing paper
“The combination of rituximab with rapamycin, mTOR inhibitor, or with rapamycin and corticosteroids were successful in inducing tolerance and preventing antibody formation in clinical trials [16, 170].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [16]
In the citing paper
“The combination of rituximab, sirolimus, and corticosteroids was also used in a recent clinical trial for GM2-gangliosidosis through CNS-directed AAV delivery (55). No vector-related adverse events was observed.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [55]
Citations
Cites
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
The journal of neuroscience : the official journal of the Society for Neuroscience.
Press, H. (1981) · Cited by 581
Jun-ichi, M., Satoshi, T., Kimi, A., Fumi, T., Akira, T., Kiyoshi, T., & Ken-ichi, Y. (1989) · Gene · doi:10.1016/0378-1119(89)90209-6 · Cited by 446
Hermoye, L., Saint-Martin, C., Cosnard, G., Lee, S.-K., Kim, J., Nassogne, M.-C., Menten, R., Clapuyt, P., Donohue, P. K., Hua, K., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2005.08.017 · Cited by 425
Gray, S. J., Nagabhushan Kalburgi, S., McCown, T. J., & Jude Samulski, R. (2013) · Gene Therapy · doi:10.1038/gt.2012.101 · Cited by 377
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease
Muramatsu, S.-I., Fujimoto, K.-I., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., Kawakami, T., Urabe, M., Kume, A., Sato, T., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.135 · Cited by 344
Biochemical consequences of mutations causing the GM2 gangliosidoses
Mahuran, D. J. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(99)00074-5 · Cited by 296
Meyer, K., Ferraiuolo, L., Schmelzer, L., Braun, L., McGovern, V., Likhite, S., Michels, O., Govoni, A., Fitzgerald, J., Morales, P., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.210 · Cited by 286
SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS
Mueller, C., Berry, J. D., McKenna-Yasek, D. M., Gernoux, G., Owegi, M. A., Pothier, L. M., Douthwright, C. L., Gelevski, D., Luppino, S. D., Blackwood, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005056 · Cited by 264
Self-citationGene Therapy for Aromatic l -Amino Acid Decarboxylase Deficiency
Hwu, W.-L., Muramatsu, S.-I., Tseng, S.-H., Tzen, K.-Y., Lee, N.-C., Chien, Y.-H., Snyder, R. O., Byrne, B. J., Tai, C.-H., & Wu, R.-M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003640 · Cited by 246
Research works printed but not linked: 1
- Taghian, T. et al. A safe and reliable technique for CNS delivery of AAV vectors in the cisterna magna. Mol. Ther. 28, 411–421 (2020). · DOI
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Phage-assisted evolution and protein engineering yield compact, efficient prime editors
Doman, J. L., Pandey, S., Neugebauer, M. E., An, M., Davis, J. R., Randolph, P. B., McElroy, A., Gao, X. D., Raguram, A., Richter, M. F., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.039 · Cited by 311
AAV-based in vivo gene therapy for neurological disorders
Ling, Q., Herstine, J. A., Bradbury, A., & Gray, S. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00766-7 · Cited by 197
Current clinical applications of AAV-mediated gene therapy
Byrne, B. J., Flanigan, K. M., Matesanz, S. E., Finkel, R. S., Waldrop, M. A., D'Ambrosio, E. S., Johnson, N. E., Smith, B. K., Bönnemann, C. G., Carrig, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.045 · Cited by 162
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
Self-citation
Metadata
- Authors
- Flotte, T. R., Cataltepe, O., Puri, A., Batista, A. R., Moser, R., McKenna-Yasek, D., Douthwright, C., Gernoux, G., Blackwood, M., Mueller, C., Tai, P. W. L., Jiang, X., Bateman, S., Spanakis, S. G., Parzych, J., Keeler, A. M., Abayazeed, A., Rohatgi, S., Gibson, L., Finberg, R., Barton, B. A., Vardar, Z., Shazeeb, M. S., Gounis, M., Tifft, C. J., Eichler, F. S., Brown, R. H., Martin, D. R., Gray-Edwards, H. L., & Sena-Esteves, M.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Washington University in St. Louis (US)
- National Institutes of Health (US)
- Harvard University (US)
- Auburn University (US)
- Corresponding author
- Flotte, Terence R.
- ORCID
- Flotte, Terence R.
- Cataltepe, Oguz
- Puri, Ajit
- Batista, Ana Rita
- Moser, Richard
- Gernoux, Gwladys
- Blackwood, Meghan
- Mueller, Christian
- Tai, Phillip W. L.
- Jiang, Xuntian
- Keeler, Allison M.
- Rohatgi, Saurabh
- Gibson, Laura
- Finberg, Robert
- Barton, Bruce A.
- Vardar, Zeynep
- Shazeeb, Mohammed Salman
- Gounis, Matthew
- Tifft, Cynthia J.
- Eichler, Florian S.
- Brown, Robert H.
- Martin, Douglas R.
- Sena-Esteves, Miguel
- Venue
- Nature Medicine
- Published
- 2022-02
- Volume
- 28
- Issue
- 2
- Pages
- 251-259
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC10786171
- OpenAlex
- W4211164289
- Cited by
- 143
- References
- 45
- Citations by year
- 2026: 26 · 2025: 29 · 2024: 36 · 2023: 34 · 2022: 18
- FWCI
- 18.09
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- Research Square (acceptedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- Funders
- BlueGenes Foundation
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- Tay-Sachs disease, AAV gene therapy, hexosaminidase A, hexosaminidase B, intrathecal gene delivery, cisterna magna, immunosuppression, stable disease, seizure control, feasibility and safety
- MeSH terms
- Dependovirus, Anticonvulsants, Humans, Tay-Sachs Disease, Genetic Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AAV gene therapy for Tay-Sachs disease. https://app.cochat.ai/papers/10.1038/s41591-021-01664-4
- The paper
- Flotte, T. R., Cataltepe, O., Puri, A., Batista, A. R., Moser, R., McKenna-Yasek, D., Douthwright, C., Gernoux, G., Blackwood, M., Mueller, C., Tai, P. W. L., Jiang, X., Bateman, S., Spanakis, S. G., Parzych, J., Keeler, A. M., Abayazeed, A., Rohatgi, S., Gibson, L., . . . Sena-Esteves, M. (2022). AAV gene therapy for Tay-Sachs disease. Nature Medicine. https://doi.org/10.1038/s41591-021-01664-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.